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cancer samples
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Abstract
Background: It is frequently assumed that pre-invasive lesions are simpler precursors of cancer and will contain a
limited subset of the genomic changes seen in their associated invasive disease. Driver mutations are thought to
occur early, but it is not known how many of these are present in pre-invasive lesions. These assumptions need to
be tested with the increasing focus on both personalised cancer treatments and early detection methodologies.
Methods: We examined genomic copy number changes in 256 pre-invasive and invasive samples from 69 oral
cancer patients. Forty-eight samples from 16 patients were further examined using exome sequencing.
Results: Evidence of a shared ancestor of both dysplasia and carcinoma was seen in all but one patient. One-third
of dysplasias showed independent copy number events. The remainder had a copy number pattern that was
similar to or simpler than that of the carcinoma. All dysplasias examined contained somatic mutations absent in the
related carcinoma.
Previously observed copy number changes and TP53 mutations were very frequently observed, and almost always
shared between dysplasia and carcinoma. Other gene changes were more sporadic. Pathway analysis confirmed
that each patient’s disease developed in a different way.
Examining the numbers of shared mutations and the rate of accumulation of mutations showed evidence that all
samples contain a population of sub-clones, with little evidence of selective advantage of a subset of these.
Conclusions: These findings suggest that most of the genomic changes driving oral cancer occur in the pre-cancerous
state by way of gradual random accumulation rather than a dramatic single event.
Keywords: Pre-cancer, Oral cancer, Tumour progression
Background
Malignant tumours have been observed to develop after
passing through various pre-cancerous stages. Seminal
work has suggested that pre-cancerous cells may need
multiple mutations to become invasive, and that these may
occur in a specific pattern, or one of a small number of
patterns, depending on the cancer type [1, 2]. Recent
advances in genomic technology have allowed more de-
tailed analysis of the timing of these events in different can-
cer types [3, 4]. Sophisticated mathematical models have
been developed to infer the evolutionary dynamics of early
and developing disease from fully invasive specimens [5, 6].
Pre-cancerous lesions are often difficult to study due to
their small size and the feasibility of obtaining tissue. Head
and neck squamous cell carcinoma (HNSCC), however, is
an excellent disease in which to study pre-cancer, in that
invasive carcinoma frequently presents alongside pre-
cancerous dysplasia, which is macroscopically visible and
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easily accessible due to its location. This has enabled
several studies to examine groups of dysplasias and carcin-
omas [7–11]. Fortuitously, HNSCC may be one of the
cancer subtypes that would benefit most from study of
pre-cancer. The recent head and neck study of The
Cancer Genome Atlas (TCGA) [12] showed that HNSCC
has a particularly mixed set of genomic abnormalities, with
few common driver genes. This suggests that the study of
early disease instead may be a useful alternative approach.
One of the main subsets of HNSCC is oral cancer.
Oral dysplasia is characterised by the presence of archi-
tectural and cytological atypia within the surface epithe-
lium. Several classification and grading schemes are
based on the World Health Organization (WHO) 2005
guidelines [13], each with varying predictive ability.
A novel binary system [14] for grading of oral dyspla-
sia has the advantage of helping clinicians make treat-
ment decisions for dysplastic lesions, especially those
which would have been categorised as moderate dyspla-
sia in the WHO 2005 classification.
Even though carcinoma is frequently described as aris-
ing from a bed of dysplasia, the relationship between
dysplasias of various grades to each other and to their
associated squamous cell carcinoma (SCC) is poorly
understood. The genomic pathways from normal tissue
through pre-cancerous stages to fully invasive disease
has not been characterised in HNSCC. Work on small
numbers of patients shows considerable variety in both
the genomic evolutionary relationships and the differen-
tially expressed pathways between HNSCC and their re-
lated dysplasias [15, 16].
In this study we attempted to better understand what
genomic changes occur along the pathway to invasion,
whether common patterns could be observed between
patients and whether the view of gradually increasing
grade leading to invasive disease would be reflected by
genomic changes. We looked at gross genomic copy
number changes in dysplasia and SCC samples from
over 50 patients, and exome sequencing of a subset of
those patients.
Methods
Samples
Patients with potential or proven cancerous oral lesions
were recruited from the Oral Surgery outpatients’ clinic
at Leeds General Infirmary and were anonymised after
providing informed consent. Blood samples were obtained
at the time of diagnostic biopsy, and formalin-fixed
paraffin-embedded (FFPE) blocks were subsequently
obtained from the hospital archives.
Following sectioning, marking of areas of dysplasia
and SCC (Additional file 1: Figure S1), and dissection,
DNA was extracted using the Qiagen QIAamp DNA
Mini Kit or QIAamp DNA micro kit. It was noted
whether dysplasia samples were high (HGD) or low
(LGD) grade, according to the binary grading system
[14], and whether they were present in the same FFPE
block as the SCC, or a different block, and therefore
slightly further away, physically, from the SCC.
Low coverage copy number sequencing
Low coverage genomic sequence data were obtained for
each patient using an updated version of previously pub-
lished protocols [17]. DNA was prepared for Illumina
sequencing using NEBNext multiplex library preparation
kits incorporating custom designed tags. Forty libraries
were pooled and sequenced together in one 2 × 100 bp
Illumina HiSeq2500 lane, giving around 0.15× coverage
per sample.
Sequencing reads were trimmed using cutadapt [18].
Genomic copy number data were produced by CNA-
norm [19] after first aligning to the human reference
genome (hg19) using BWA [20]. Breakpoints were called
using DNAcopy [21]. Human papilloma virus (HPV) in-
fection was tested by re-aligning the data to known viral
genomes [22].
Tumour cell content was estimated using CNAnorm,
in conjunction with histological examination. Adjusted
copy number profiles were then compared as groups of
similar samples (LGD, HGD, SCC) and between different
samples from the same patient. The differences and/or
similarities between dysplasias and associated SCCs were
noted. The fraction of genome altered was calculated by
summing the number of bases of autosomal genomic
gain or loss and dividing by the size of the autosomal
genome.
Exome sequencing
A subset of patients was selected for further analysis if
their DNA from dysplasia and SCC was of sufficient
quality for adequate copy number libraries to be pro-
duced, if the copy number data showed evidence of a
disrupted genome, and if the samples proved to be HPV
negative. All SCC samples had a tumour cell content of
over 70%. All dysplasia samples contained 100% dysplas-
tic tissue.
For each patient, the exomes of matching blood,
dysplasia and SCC were sequenced using the Sureselect
Human all Exome Kit (Agilent) to an average of 125×
coverage. Reads were trimmed using cutadapt, aligned to
the human genome using BWA and processed using the
GATK pipeline [23]. Mutations were called using
Varscan2 [24] in somatic mode. Putative variants were
initially filtered to remove any with a Varscan somatic
score of 10 or below (p > 0.1) and any supported by
fewer than three reads.
Following mutation calling, the variant allele frequency
(VAF) of each mutation was calculated. The VAFs of
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mutations which were either unique to each sample or
shared between dysplasia and SCC were compared both
as histograms and dot plots. As mutation calls with a
VAF <0.12 were more likely to be caused by sequencing
errors or FFPE artefacts [6], these analyses were per-
formed both with and without those calls with a VAF
<0.12. The validity of this cutoff was confirmed by ana-
lysis of PCR validation of exome data from a similar co-
hort of previously published HNSCC FFPE samples [15]
(Additional file 1: Figure S2).
Examining neutral tumour evolution and mutation rate
Following the recent work of Williams et al. [6], the
VAFs of each sample were used to test for the presence
or absence of neutral evolution. High VAF mutations
(>0.24) are more likely to be clonal so were removed, as
were low values (<0.12), which were more likely to be er-
rors or artefacts. The remaining mutations represent the
expanding and diversifying lesion and capture the sub-
clonal architecture. The cumulative number of muta-
tions, M(f ), was plotted against the inverse of the VAF,
1/f. The R2 goodness of fit for each plot was calculated,
with values over 0.98 indicating that the sample was fol-
lowing the neutral evolution model.
For those samples following the neutral model, muta-
tion rates were calculated as the gradient of the M(f )
against 1/f plots divided by the 30-Mb exome size, and
expressed as mutations per base per effective cell div-
ision. This was calculated for all mutations and for each
mutation type separately.
Analysing functional variants
To focus on those mutations which were likely to be
driving the disease in each patient, mutations were fil-
tered based on cellular frequency and possible effect on
protein function The minimum possible cellular fre-
quency of each mutation was calculated using the VAF,
adjusted for normal cell contamination and copy num-
ber. For instance, in a triploid region of the genome in a
sample with 70% tumour cell content, each tumour cell
chromosomal copy will contribute 23.3% of the reads, so
a mutation in over 50% of cells will have a minimum
VAF of 11.7%. The putative effects of each mutation
were predicted using the Variant Effect Predictor [25].
Mutations were kept if they were present in over 50% of
cells and had a somatic score of over 15 (p < 0.05), in
either dysplasia or SCC, and if they had a possible effect
on protein function, namely: anything affecting a splice
site, frameshifts, stop gained or lost, coding deletions or
insertions, initiator codon variants, incomplete terminal
codon variants, exon elongations, truncation mutations,
or missense mutations that were labelled as either pos-
sibly or probably damaging or deleterious. If a mutation
passed filters in one sample but was present in lower
cellular frequency in the paired sample, it was counted
as present in both samples.
Pathway analysis
For each patient, lists of genes passing filters were split
into three lists according to whether they were found in
dysplasia only, SCC only or shared. These lists were
compared to lists of genes from the KEGG [26, 27] data-
base in pathways previously associated with HNSCC:
calcium signalling, cell cycle, DNA replication, ERBB
signalling, JAK-STAT signalling, MAPK, NOTCH
signalling, PI3K, P53 signalling, phosphatidylinositol sig-
nalling, VEGF signalling, WNT signalling and hedgehog.
Lists of genes from HNSCC exome papers [28], the can-
cer gene census [29] and TCGA head and neck study
[12] were also used.
A more agnostic approach was taken by importing the
gene lists into the DAVID functional annotation tool
[30, 31], and keeping those gene ontology (GO) terms
that were enriched with a p value of 0.05 or better.
Results
Samples
Data were collected from 69 patients. Fifty-nine patients
provided enough DNA from both dysplasia and SCC
samples for comparative analysis, totalling 256 samples
(Additional file 1: Table S1).
Copy number patterns
The various LGD, HGD and SCC (n = 38, 59 and 149,
respectively) samples were examined individually and
cumulatively. While there was considerable variation be-
tween samples, individually, LGD samples were more
likely to have fewer genomic changes than HGD or SCC
samples (median fractions genome altered were 0.12,
0.38 and 0.30, respectively). A Mann–Whitney test com-
paring the distributions of fractions of genome altered
between LGD and HGD samples gave a p value of
4.76 × 10−9. Comparing LGD and SCC samples gave a p
value of 2.57 × 10−7, while comparing HGD and SCC
only gave a p value of 0.057. This was confirmed by cu-
mulative frequency plots (Fig. 1). The HGD and SCC
groups were almost indistinguishable and matched the
expected frequencies previously observed in TCGA
HNSCC series. The mean copy number profiles of the
two groups had a Pearson’s correlation coefficient of
0.92. The correlations between the mean LGD copy
number profile and the mean HGD and SCC profiles
(both 0.81) were lower than the HGD/SCC comparison.
Every region of common gain or loss in one group was
reflected in the others. Only the relative frequencies of
some of them varied slightly. When the respective
frequencies of the most common regions of change in
the three sample groups were compared (Table 1) most
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regions followed the expected pattern, predicted by the
overall fraction of genome altered and sample numbers.
Gain of chromosome 7 occurred in more LGD samples
than would be expected, but this was not significant
after adjusting for multiple testing. Only gain of chromo-
some arm 8q showed a significant deviation, again being
present in more LGD samples than expected, indicating
that, where present, it is a particularly early event.
Comparing patterns to those seen in TCGA data [12],
these patients showed similar regions of gain and loss,
albeit with a few differences. In the HPV-associated pa-
tients, neither amplification of the E2F1 gene nor loss of
TRAF were observed. In the HPV-negative patients, loss
of TP53 was not observed. However, local gain of 3q26-
3q28 was common, occurring in 23 out of 59 patients as
either a partial arm gain or local amplification. Similarly,
local amplification of 11q23 was observed in 23 patients.
Samples were also examined in the context of other
samples from the same patient. For those patients from
which LGD and HGD samples were analysed, the mean
change across the genome seen in the HGD but not the
matching LGD was calculated. A similar analysis was
performed with patients with matching SCC and HGD
samples (Fig. 2). For the LGD–HGD pairs, the changes
seen in HGD samples but not their matched LGD samples
very closely mirrored the cumulative frequency plot of
SCC samples (correlation coefficient 0.82). In contrast, the
changes seen in SCC samples but not the matched HGD
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Fig. 1 Cumulative copy number frequencies for LGD, HGD and SCC cohorts. The x-axis denotes genomic position, while the y-axis denotes the proportion
of samples with a gain (red) or loss (blue) at that position. A summary of the fraction genome altered for each sample group is displayed on the right
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samples appeared to be more random, with only a 0.51
correlation coefficient with the overall SCC pattern.
Patients were subdivided into groups according to the
relationships between patterns of the dysplasia and SCC
samples: (1) dysplasia and SCC showed some common
features, but each displayed other independent features;
(2) dysplasia and SCC were nearly identical; (3) the
dysplasia showed a subset of the alterations seen in the
SCC, or the dysplasia had a flat profile; (4) both dyspla-
sia and SCC had flat profiles. Examples of these relation-
ships are shown in Figs. 3, 4 and 5. Some patients
provided more than one sample and could sometimes be
classed into more than one of these groups, depending
on which samples were compared.
Percentages of patients in each of these groups are
shown in Fig. 6, as well as a patient-by-patient break-
down. Samples are classed according to whether the
dysplasias were LGD or HGD and, separately, whether
the dysplasias were in the same or a different block to
the SCC. Some patients were counted multiple times.
For example a patient might have had an adjacent HGD
with pattern 1, an adjacent pattern 1 LGD and a distant
pattern 2 LGD. This patient would be counted as
pattern 1 in the HGD analysis, both 1 and 2 in the LGD
Table 1 Percentage frequencies of the most common copy
number events in LGD, HGD and SCC samples
LGD HGD SCC P value
3p loss 28.95 72.46 0.72 0.3994
4p loss 13.16 44.93 0.33 0.9453
5q loss 23.68 69.57 0.56 0.9787
9p loss 26.32 65.22 0.50 0.7044
11 pq loss 18.42 50.72 0.36 0.7893
18q loss 7.89 42.03 0.50 0.0646
3q gain 36.84 68.12 0.60 0.2041
5p gain 39.47 62.32 0.51 0.0428
7 pq gain 39.47 47.83 0.50 0.0067
8q gain 50.00 57.97 0.59 0.0009
12p gain 7.89 31.88 0.36 0.2404
Expected 12 38 30
The p values that each event differs from the expected frequencies were
calculated from the overall fraction of genome altered and total sample
number for each group using a chi-squared test. As 11 regions were tested,
p values below 0.0045 are considered significant
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analysis, 1 for the adjacent dysplasia analysis and 2 for
the distant dysplasia analysis.
Patterns 1, 2 and 3 accounted for all but one patient
and were found at very similar overall frequencies.
Comparing LGD and HGD samples, both types had very
similar frequencies of pattern 1 (related but independ-
ent), the LGD samples had relatively higher frequencies
of pattern 3 (dysplasia being a simpler version of the
SCC), while the HGD samples had a relatively higher
proportion of pattern 2 (SCC and dysplasia very similar).
A chi-squared test showed this result to be significant
(p = 0.0264).
When comparing samples with distant and adjacent
dysplasia–SCC pairs, the distant samples had a relatively
Fig. 3 Copy number class 1. Copy number plots from an LGD and SCC sample from the same patient. The x-axis shows genomic position and the
y-axis shows copy number ratio. Red dots indicate a ratio above 1 (gain) while blue dots indicate a ratio below 1 (loss). Some genomic events (vertical
red lines) are shared between samples, while some (blue vertical lines) are unique to each sample. On the right are high-resolution histology images of
the respective samples
Fig. 4 Copy number class 2. Both dysplasia and SCC samples have multiple copy number events, all of which are shared by both samples
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Fig. 5 Copy number class 3. All of the events in the dysplasia are also found in the SCC, while the SCC has its own unique events
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lower frequency of pattern 2 and relatively higher fre-
quencies of patterns 1 and 3. The differences were not
as striking as in the LGD–HGD comparison and, conse-
quently, this result was not significant (p = 0.6296).
Exome sequencing
Sixteen patients were selected for exome sequencing of
one dysplasia and one SCC sample each. Sequencing sta-
tistics for each sample are shown in Additional file 1:
Table S2. Between 1146 and 7835 (median 2523) somatic
variants were called in either the SCC or dysplasia per
patient with initial filters in place. Relatively small num-
bers of these variants, between 1.9 and 15.9% (median
9.5%) were shared between dysplasia and SCC samples
from the same patient. A patient-by-patient breakdown
of these results is shown in Additional file 1: Figure S3.
When VAFs from paired samples were compared, every
patient had a number of private mutations and a diffuse
cluster of shared mutations. An example is shown in Fig. 7,
with all samples shown in Additional file 1: Figure S6. The
private mutations were spread over a range of VAFs, so
were not restricted to minor sub-clones. More likely they
were mutations which were locally clonal but globally sub-
clonal and simply a reflection of sampling. For all 16 pa-
tients (16 SCC and 14 dysplasias), the shared mutations
had a significantly different distribution of VAFs than the
total mutations, with higher values. For eight patients, this
was maintained even after VAFs <0.12 were removed. How-
ever, the shared VAFs were not confined to the higher end
of the range of values. For those samples with a significantly
different distribution, the VAFs of shared events still cov-
ered the entire range, but with a shift towards higher values.
Higher VAFs for shared mutations would indicate that
these represented earlier, more common sub-clones, or the
result of a selective sweep, with the remaining, low VAFs
events being private mutations which occurred since then.
The observed similar, or overlapping, distributions are more
indicative of spatial sampling, with a mixture of sub-clones
being spread throughout the lesion with locally variable
population densities.
To ensure that these shared mutations were not sim-
ply caused by recurrent FFPE artefacts which could
occur in any sample, shared mutation calls between and
within patients were compared. For every sample, the
number of mutation calls shared with every other sam-
ple was collected, both from the same patient and from
different patients. Comparing numbers of shared calls
between patients establishes a baseline level of how
many shared calls are likely FFPE artefacts. These results
are summarised in Additional file 1: Figure S5 and show
that for every VAF range, the number of shared muta-
tions within a patient was significantly greater than the
number of presumably false calls shared between
patients. For the calls with a VAF over 0.1, there was no
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overlap at all between the distributions. The sample pair
with the fewest number of shared mutations within a
patient had more shared calls than the pair with the
most between-patient calls.
No patient showed evidence of more than one cluster of
mutations, which might reflect distinct sub-clones which
were rare in one sample and more common in the pair, as
has been seen in leukaemia [32], and might be a result of
a new, selectively advantaged sub-clone emerging.
We tested for this putative absence of sub-clonal selec-
tion by plotting the rate at which sub-clonal mutations
emerged. Neutral evolution will see a steady accumula-
tion of mutations. If a new sub-clone causes a selective
advantage, then the measured number of mutations per
cell division will drop, as the new sub-clone begins to
dominate its surroundings, reducing heterogeneity. All
16 SCC samples and 14 of the 16 dysplasias had an R2
value over 0.98, which has been calculated to be a strin-
gent indicator of neutrality [6]. Examples of neutral and
non-neutral samples are in Fig. 8, with all samples
shown in Additional file 1: Figure S7. Both the non-
neutral samples showed a reduction of the mutations
per cell division over time, indicative of a selectively
advantaged sub-clone emerging at an early stage. The
lack of this curve in the matching SCC suggests that this
clone is fixed in the population by the time the disease
becomes invasive, and that further sub-clonal evolution
confers no further selective advantage to growth rate.
The model uses an “effective cell division rate”, which is
division minus cell death. It is not clear if these results
show the true emergence of a sub-clone with a selective
growth advantage over its neighbours, or whether the
overall growth of the lesion increased as the cells moved
towards a more invasive phenotype, free of the control
mechanisms of normal tissue.
These results also allow for estimations of mutation
rate which are less skewed by sequence errors and FFPE
artefacts than mere counting of variants, using the gradi-
ent of the graphs in the region between the low VAFs,
which may be artefacts, and the high VAFs, which may
be clonal. While there was variation between samples
(Fig. 9), all rates were in line with those taken from
TCGA lung series, as calculated by Williams et al. [6].
One sample (PG192) was a clear outlier, with mutation
rates more than twice that of the next highest patient.
Five patients had a higher rate for dysplasia, 11 for SCC.
Again, it should be noted that these rates are mutations
per base per effective cell division. A putatively high rate
may actually be a normal rate with low cell division—a
slow growing disease.
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Fig. 8 Cumulative distribution of sub-clonal allele frequencies (VAF 0.12–0.24). Neutral evolution is indicated by a straight line with R2 values over
0.98. The dysplasia (left) and SCC (right) from examples of putative neutral (PG004, top) and non-neutral (PG144, bottom) evolution are shown
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Since we observed that most samples demonstrated
essentially neutral evolution, with sub-clonal mutations
having little effect on tumour growth, it appeared that
potential driver events were more likely to be early,
clonal mutations. Therefore, variants were filtered to re-
move those present in less than 50% of cells in both dys-
plasia and SCC samples, and those which would have no
predicted effect on the protein expressed. The results of
this more stringent filtering are shown in Additional file 1:
Figure S4. Between 44 and 179 variants per patient passed
the filters (median 97). These mutations, with their pre-
dicted effects, are listed in full in Additional file 2. The
filtered variants were more likely to be shared between
dysplasia and SCC samples than the unfiltered variants
(p < 0.0001). One patient shared 2.7% variants while the
rest shared between 11.8 and 53.3% (median 34.3%). All
patients had fewer mutations in dysplasia than SCC
samples. All but two had more shared mutations than
dysplasia-only changes. All but one patient had more
SCC-only mutations than shared. Neither the number
nor proportion of shared mutations correlated with the
total number of mutations per sample. Mutations are
listed in Additional file 1: Table S3.
To further investigate putative driver genes, the variants
were filtered against lists of genes in pathways predicted to
be altered in cancer, as well as lists of genes observed to be
frequently mutated in HNSCC. These results are shown in
Fig. 10, Additional file 1: Figure S8 and Additional file 1:
Table S3. The numbers of genes affected varied consider-
ably between patients—between 3 and 31 (median 10).
Between 0 and 67% of these were shared between samples.
The relationships between the number of SCC-only, shared
and dysplasia-only mutations was not as straightforward
has had been seen in the numbers of filtered mutations.
Only eight patients had any dysplasia-only changes in sus-
pected cancer genes. All patients had some SCC only
changes. One had no shared events. Four patients had
more shared than SCC mutations, 11 had more SCC than
shared, while one had equal numbers of shared and SCC-
only changes. No pattern could be observed linking these
numbers to either dysplasia grade or whether the dysplasia
was adjacent or distant to the SCC. Similarly, the propor-
tion of shared variants was not significantly different to the
initial list of filtered variants (p = 0.921). If these were all
driver genes, then it would be expected that they would be
more likely to be early, shared events than the list of filtered
genes. As this was not the case, it seems that many of the
genes on these list were merely potential drivers, rather
than actively driving these lesions.
Particular attention was paid to genes present in over
10% of samples in TCGA HNSCC survey. TP53 was mu-
tated in 11 of the 16 patients. For eight of these patients,
the TP53 mutation was shared between the SCC and
dysplasia, indicating that it was an early event. Two
patients had mutated TP53 in their SCC but not their
dysplasia samples (both of these dysplasia samples were
in a different FFPE block to the SCC). One patient had
separate TP53 mutations in both the dysplasia and the
SCC, which were not shared between the two. Other
TCGA genes were not shared as frequently: seven genes
shared, ten SCC-only and three dysplasia-only. Interest-
ingly, one of the samples with no TP53 mutations had
the highest numbers of other common TCGA genes
mutated.
Finally, the filtered variants were used to generate lists of
Gene Ontology (GO) terms significantly affected by the
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dysplasia-only, shared and SCC-only mutations from each
patient. These results are shown in Additional file 1: Table
S4. For 11 of the 16 patients, no dysplasia-only GO terms
were significantly enriched. Every patient had some GO
terms enriched that could realistically be linked to carcino-
genesis, such as apoptosis, cell adhesion, cell differentiation,
response to wounding, etc. However, there was little over-
lap between patients, or any particular pattern of some
terms appearing in the shared lists and some in the SCC-
only lists.
Discussion
The frequent close physical association between oral
dysplasia and invasive carcinoma has led to the common
assumption that the relationship between the two is
sequential, with one arising from the other [33–36]. A
Cancer Genes Mutated
N
u
m
b
e
r 
o
f 
M
u
ta
ti
o
n
s
0
5
1
0
1
5
2
0
2
5
3
0
Dys only - Adjacent
Shared - Adjacent
SCC only - Adjacent
Dys only - Distant
Shared - Distant
SCC only - Distant
P
G
0
3
8
P
G
1
2
3
P
G
0
0
4
P
G
0
7
9
P
G
1
2
2
P
G
1
3
7
P
G
1
7
4
P
G
1
9
2
P
G
1
0
5
P
G
0
4
9
P
G
0
6
3
P
G
1
0
8
P
G
1
2
9
P
G
1
3
6
P
G
1
4
4
P
G
1
8
7
TP53 11
TBP 7
CDKN2A 5
NOTCH2 4
CDC27 3
ZFHX4 3
CSMD3 3
NOTCH1 3
FAT1 2
ITGA10 2
FLG 2
MAML2 2
ITPR1 2
NSD1 2
NCOA2 2
ZNF521 2
PBRM1 2
LAMA5 2
AJUBA 2
ITGB4 2
TCL1A 2
MAP3K12 2
PIK3CA 1
PTEN 1
NFE2L2 1
CASP8 1
Fig. 10 The variants seen affecting putative cancer pathways or lists of common HNSCC genes. TP53 mutations are shown in gold. Other
common TCGA mutations are shown in silver. Any putative cancer gene mutated in more than one patient plus all common TCGA mutations are
listed. Shades of orange indicate adjacent dysplasia–SCC pairs. Shades of blue indicate distant pairs. For each patient, the number of dyplasia-only,
shared and SCC-only variants are shown. There are two rows for each gene; the top row indicates that it is mutated in dysplasia and the bottom
row in SCC. So for TP53, for example, PG105 has a SCC-only mutation, PG038 has a mutation which is shared, and PG123 has different mutations
in the dysplasia and SCC samples. All genes are shown in Additional file 1: Figure S8
Wood et al. Genome Medicine  (2017) 9:53 Page 11 of 14
common approach is to observe groups of either dyspla-
sias or carcinomas and compare them to each other,
with some evidence suggesting that lower grade dyspla-
sias have lower risk of progression [7, 8]. Recent
comprehensive characterisation of fully invasive disease
has suggested that either TP53 mutation or HPV infec-
tion are almost universal, along with a small number of
common copy number patterns, but that changes to
other genes were far more heterogeneous, with only six
other genes mutated in over 10% of samples, and none
of those in more than 25% [12].
The purpose of this study was to investigate the genomic
similarities and differences between LGD, HGD and SCC.
As well as studying groups of samples of similar grade, we
were able to observe the changes in individual patients,
which is important given how few common changes there
are in HNSCC. Was it the case that certain groups of
changes always occurred in a specific order, and how simi-
lar are the dysplasia and carcinoma samples from each pa-
tient? Additionally, this work also allowed us to test the
hypothesis that dysplasia is a simpler precursor to invasive
disease. Seminal work in colorectal cancer has suggested a
simple step-wise genomic development from normal tissue,
through pre-cancerous stages of increasing grade to fully
invasive disease [2]. In previous work we have examined
clonal relationships between dysplasia and carcinoma in
five patients, which suggested that the relationships are
sometimes complex and are not always a simple progres-
sion [15]. By working with larger numbers of patients, we
were able in this study to examine trends between the dif-
ferent grades of disease.
By examining the frequencies of copy number gains
and losses in the cohorts of LGD, HGD and SCC sam-
ples, genomic damage did appear to be linked to grade.
HGD samples showed copy number patterns almost
indistinguishable from those of SCC samples. Only a mi-
nority of LGD samples displayed these changes, with
many changes in HGD and SCC samples absent. These
findings suggest that these copy number changes were
not necessary to develop LGD, and tended to occur at
some point in the development from LGD to HGD. The
HGD samples contained all the common copy number
changes seen in the invasive disease, so the final trigger
for invasion was more likely to be a gene mutation or
some other transcriptomic, epigenetic or environmental
change. Forty percent of dysplasia samples displayed
independent evolution of the genome absent in the SCC,
showing that the samples taken were not the direct
progenitors of the invasive disease.
A similar pattern was observed when examining the
shared and private mutations seen in the exome data.
The shared mutations tended (but not overwhelmingly)
to have higher VAFs, indicative of early sub-clones. The
presence of large numbers of low VAF shared mutations
in all samples does suggest that the same minor sub-
clones are present in both the dysplastic and invasive
part of a lesion, and that mutationally similar cells may
appear histologically different, perhaps depending on the
status of the majority of their neighbours. If, instead, the
invasive process had begun with a single sub-clone in
the dysplasia, which proceeded without mixing with any
of its neighbours, then all the shared mutations would
have a high VAF in the SCC sample.
We examined this gradual model of tumour evolution
by testing whether mutations were accumulating accord-
ing to a neutral or selective pattern. Two dysplasia
samples showed evidence of early selection, but the
remaining dysplasias and all SCCs followed the neutral
predictions. Neutral evolution was even found in patients
such as PG049, where all the known driver mutations oc-
curred only in the SCC sample, which might suggest a late
occurring selective advantage. This could be due to the
fact that only one dysplasia sample was taken for each
patient. More extensive sampling might have detected
these mutations in a region of the dysplasia more directly
ancestral to the SCC, as we sometimes found when we
sampled multiple regions of a smaller group of patients
[15]. An alternative explanation is that these driver muta-
tions only affected the invasive potential of the lesions and
had less effect on their growth rate. Even though we only
sequenced 16 patients, no other cancer type examined by
Williams et al. [6] displayed neutral evolution in more
than half of the patients examined. If we were expecting
50% of samples to be neutral, observing neutrality in 14
has a p value of 0.0027. This unusually high frequency
could be explained by the natural history of HNSCC. It is
typically caused by decades of tobacco use, with attendant
constant gradual mutation in the oral epithelium. How-
ever, in contrast with lung cancer, oral cancer is in one of
the most sensitive and accessible regions of the body, so is
frequently diagnosed extremely early, possibly before the
emergence of later, selectively advantaged populations.
Since no samples showed evidence of a late-emerging
driver clone, we concentrated on mutations in a high
proportion of cells (in either dysplasia or SCC) which
might have a putative effect on protein function.
As with the copy number analysis, once samples
within patients were compared, the variability between
patients was stark, in both numbers of overall mutations
and the proportions of those mutations which were
dysplasia-only, shared, or SCC-only.
Known cancer genes were very infrequently mutated
only in the dysplasia samples, suggesting that whilst dys-
plasia may sometimes evolve away from the recent com-
mon ancestor, much of this evolution consists of the
accumulation of passenger events. Cancer gene mutations
were equally likely to be shared, or SCC-only, depending
on the patient. TP53 mutations, however, were almost
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always shared, indicating that, where present, they were
necessary, early events in the development of HNSCC.
When examining GO terms, very few terms were
enriched from the dysplasia-only lists. This confirmed
the hypothesis that the many mutations accumulating as
dysplasia and SCC evolve away from the common
ancestor are sporadic passengers. Once mutations that
perturb a pathway begin to accumulate, this fraction of
cells is more likely to be represented in the invasive
disease. Which pathway is perturbed does not appear to
be shared between patients.
Conclusions
Taken together, these results present a fascinating insight
into the early stages of HNSCC development. Copy num-
ber changes and point mutations do appear to accumulate
as the disease moves from normal tissue to LGD, HGD
and SCC, but there does not appear to be a step-wise ap-
pearance of a wave of sub-clones, each replacing its ances-
tor in a selective sweep. The finding of multiple low VAF
shared mutations raises the intriguing possibility that the
behaviour of cells may be influenced by their neighbours,
as has been observed in other cancer types [37–40]. We
do see an increase in mutations and copy number changes
as we move from LGD to HGD to SCC, but this does not
appear to correspond to a matching change in selective
advantage. It is speculation at this stage, but it could be
that new sub-clones do not increase in relative frequency
in a lesion because they create an environment in which
their sister sub-clones can also flourish. Similar to the
concept of field cancerisation [36], the long period of to-
bacco exposure in most patients may produce a sub-
clinical population of cells which are primed for disease,
and once a suitable combination of mutations emerges,
not just the cells directly mutated change their phenotype.
Our findings could have significance for future efforts to
monitor patients with dysplasia, when deciding whether or
not to intervene. Although dysplasia samples did have muta-
tions not found in the associated SCC, these were not usually
in known cancer genes. Mutations in cancer genes in the
dysplasia samples were mostly also found in the associated
SCC samples, so could be used as markers of progression.
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